The ⑀4 allele of apolipoprotein E (APOE) and traumatic brain injury (TBI) are both risk factors for the development of Alzheimer's disease (AD). These factors may act synergistically, in that APOE4ϩ individuals are more likely to develop dementia after TBI. Because the mechanism underlying these effects is unclear, we questioned whether APOE4 and TBI interact either through effects on amyloid-␤ (A␤) or by enhancing cell death/tissue injury. We assessed the effects of TBI in PDAPP mice (transgenic mice that develop AD-like pathology) expressing human APOE3 (PDAPP: E3), human APOE4 (PDAPP:E4), or no APOE (PDAPP:EϪ/Ϫ). Mice were subjected to a unilateral cortical impact injury at 9-10 months of age and allowed to survive for 3 months. A␤ load, hippocampal/cortical volumes, and hippocampal CA3 cell loss were quantified using stereological methods. All of the groups contained mice with A␤-immunoreactive deposits (56% PDAPP: E4, 20% PDAPP:E3, 75% PDAPP:EϪ/Ϫ), but thioflavine-Spositive A␤ (amyloid) was present only in the molecular layer of the dentate gyrus in the PDAPP:E4 mice (44%). In contrast, our previous studies showed that in the absence of TBI, PDAPP:E3 and PDAPP:E4 mice have little to no A␤ deposition at this age. After TBI, all of the A␤ deposits present in PDAPP:E3 and PDAPP: EϪ/Ϫ mice were diffuse plaques. In contrast to the effect of APOE4 on amyloid, PDAPP:E3, PDAPP:E4, and PDAPP:EϪ/Ϫ mice did not differ in the amount of brain tissue or cell loss. These data support the hypothesis that APOE4 influences the neurodegenerative cascade after TBI via an effect on A␤.
The ⑀4 allele of apolipoprotein E (APOE) and traumatic brain injury (TBI) are both risk factors for the development of Alzheimer's disease (AD). It was first found that APOE4 was a risk factor for AD in 1993 (Strittmatter et al., 1993) , and numerous studies have confirmed this association. Several studies have found that individuals who sustained moderate to severe head injury are more likely to develop dementia and AD (Mayeux et al., 1993 (Mayeux et al., , 1995 Plassman et al., 2000) . These risk factors appear to act synergistically, in that individuals who are APOE4ϩ are even more likely to develop dementia if they sustain TBI at some time in their life. For example, APOE4ϩ individuals were 10 times more likely to develop AD after TBI than those who were APOE4Ϫ, whereas APOE4 in the absence of injury was associated with only twice the risk (Mayeux et al., 1995; Tang et al., 1996) .
Although the mechanisms underlying these effects are unclear, some evidence suggests that both APOE4 and TBI may influence the risk of AD via interactions with the amyloid-␤ (A␤) peptide.
For example, A␤ deposition can be found in ϳ30% of people who die shortly after TBI (Roberts et al., 1991 (Roberts et al., , 1994 ; a significant percentage of these patients are APOE4ϩ (Nicoll et al., 1995 (Nicoll et al., , 1996 . In addition, analysis of CSF from TBI patients revealed elevated levels of A␤ 1-42 for up to a week after TBI, in comparison with both controls and AD patients (Raby et al., 1998; Emmerling et al., 2000) . In an evaluation of the effect of APOE3, APOE4, or APOEϪ/Ϫ in transgenic (TG) mice after TBI, greater mortality was observed in APOE4 mice, whereas APOE3 mice exhibited better neurological function between 3 and 11 d after TBI (Sabo et al., 2000) . Although APOE3 mice had less tissue loss after TBI than APOEϪ/Ϫ or wild-type mice, there was no significant difference in tissue loss comparing APOE3 with APOE4 mice. The mice studied did not express human amyloid precursor protein, so A␤ deposition did not occur (Sabo et al., 2000) .
Because the mechanism by which the APOE genotype and TBI interact to influence dementia remains unresolved, we questioned whether APOE4 and TBI interact through effects on A␤, enhancement of cell death or tissue injury, or both. We used a well characterized model of TBI (Smith et al., 1995) and assessed the histological outcome in PDAPP mice (a TG mouse that develops AD-like pathology) that either lack apoE or express human APOE3 or APOE4.
MATERIALS AND METHODS
PDAPP mice expressing amyloid precursor protein (APP) with a mutation that causes familial AD (APP V717F ) (Games et al., 1995) but lacks the mouse A POE gene (PDAPPϩ/ϩ, A POEϪ/Ϫ) (Bales et al., 1997) were bred with mice that express human A POE under control of the glial fibrillary acidic protein (GFAP) promoter (GFA P-A POE3 and GFA P-A POE4 ) (Sun et al., 1998) . The GFA P-A POE3 and GFA P-A POE4 mice were all on a C57BL /6 mouse A POEϪ/Ϫ background. The breeding produced three types of TG mice (Holtzman et al., 2000) : PDAPPϩ/Ϫ, A POEϪ/Ϫ (PDAPP:EϪ/Ϫ), PDAPPϩ/Ϫ, A POE3ϩ/Ϫ (PDAPP:E3), and PDAPPϩ/Ϫ, A POE4ϩ/Ϫ (PDAPP:E4). Human A POE3 and A POE4 TG mouse lines used in this experiment were matched for APOE levels (Sun et al., 1998) . The mice were subjected to a controlled cortical impact injury (left hemisphere) (Smith et al., 1995) at 9 -10 months of age, while under pentobarbital (65 mg / kg) anesthesia. This injury results in underlying cortical damage with shrinkage of the hippocampus and CA3 cell loss. Mortality rates immediately after TBI were similar in all groups (ϳ25%), resulting in sample sizes of n ϭ 4 PDAPP: EϪ/Ϫ, n ϭ 10 PDAPP:E3, and n ϭ 9 PDAPP:E4. At 12-13 months (3 months after injury), all mice were killed; their brains were removed, fixed, frozen, and sliced into 50 m coronal sections from the genu of the corpus callosum through the caudal extent of the hippocampus (Holtzman et al., 2000) . Three sets of sections, each containing every sixth slice, were collected from each brain. The sections were then mounted and stained with pan anti-A␤ antibody (Biosource, C amarillo, CA), cresyl violet, or 4Ј,6Ј-diamidino-2-phenylindole (DAPI). Animals with A␤-immunoreactive (IR) deposits were f urther analyzed using the C avalieri point-counting method with stereological software (Stereo Investigator; MicroBrightField Inc., Colchester, V T) to quantif y the area covered by A␤-IR deposition (A␤ load) as described previously (Holtzman et al., 2000) .
To obtain volume estimates of the hippocampus and cortex, cresyl violet-stained sections were analyzed. Hippocampal measurements were taken from every sixth section through the entire structure; cortical measurements were taken from the first three anterior sections containing hippocampal tissue. The cortical region of interest was defined as cortical tissue dorsal to the superior extent of the thalamus. The volumes of the hippocampus and defined cortical region were determined using the Stereo Investigator software. The percentage of hippocampal and cortical tissue lost (ipsilateral vs contralateral to injury) was calculated for each group.
In most animals, the inferior blade of the CA3 hippocampal field exhibited a focal lesion ipsilateral to the injury, also noted in rodent models of TBI (Nakagawa et al., 1999) . CA3 neuronal counts were obtained using DAPI-stained sections through the entire extent of the hippocampus. A randomly selected subset of brains was analyzed (n ϭ 4 PDAPP:EϪ/Ϫ; n ϭ 5 PDAPP:E3; n ϭ 5 PDAPP:E4), and measurements were taken from all sections that contained CA3 neurons. In each section, the inferior blade of CA3 was traced using the computer. Estimates of neuronal numbers were obtained with the optical fractionator technique using Stereo Investigator software. The area was traced with a 4ϫ lens, and neurons were counted throughout the traced area using systematic random sampling with a 100ϫ lens.
The data were analyzed using Statistica 6.0 (Statsoft Inc., T ulsa, OK), and ␣ levels of p Ͻ 0.05 were set for significance. The frequency of A␤ deposition was analyzed using 2 analysis. The percentage of the hippocampus covered by A␤-IR was analyzed with a two-way ANOVA that included one between-subjects factor (genotype: PDAPP:E3 vs PDAPP:E4 vs PDAPP:EϪ/Ϫ) and one within-subjects factor (hemisphere: ipsilateral vs contralateral to impact). Cortical and hippocampal volume estimate data were analyzed with two-way ANOVAs that included one between-subjects factor (genotype: PDAPP:E3 vs PDAPP:E4 vs PDAPP:EϪ/Ϫ) and one within-subjects factor (hemisphere: ipsilateral vs contralateral to impact). CA3 neuronal counts were analyzed with a two-way ANOVA that included one between-subjects factor (genotype: PDAPP:E3 vs PDAPP:E4 vs PDAPP:EϪ/Ϫ) and one within-subjects factor (hemisphere: ipsilateral vs contralateral to impact).
RESULTS

A␤ analysis Frequency and pattern of A␤ deposition
We found previously that PDAPP mice expressing human APOE3 or APOE4 do not develop A␤ deposition until ϳ15 months of age, when PDAPP:E4 mice in particular begin depositing A␤ and amyloid (Holtzman et al., 2000; Fagan et al., 2002) . In contrast, after TBI, we found that a high percentage of braininjured PDAPP:E4 mice had A␤ deposition by 12-13 months of age. In the PDAPP:E4 mice, 55.6% had A␤-IR deposits within the hippocampus and 44% had thioflavine-S-positive A␤ (fibrillar amyloid) in the molecular layer (ML) of the dentate gyrus (Table  1) . Among the PDAPP:E3 mice, only 20% had hippocampal A␤-IR deposits, all of which were diffuse plaques. No PDAPP:E3 mice had fibrillar amyloid deposition. Significantly more PDAPP:E4 mice had ML A␤-IR deposits compared with PDAPP:E3 mice ( 2 , p Ͻ 0.02) (Fig. 1) . This is notable because A␤ deposition in the ML of PDAPP mice coincides with the onset of fibrillar A␤ deposition and neuritic plaque formation (Holtzman et al., 2000; Fagan et al., 2002) . Thus, only the PDAPP:E4 mice developed neuritic plaque formation after TBI at this age. Assessment of A␤ 40 and A␤ 42 immunostaining of PDAPP:E3 and PDAPP:E4 mice revealed the same pattern of staining as that seen with the pan-A␤ antibody (data not shown). Qualitatively, the same differences between PDAPP:E3 and PDAPP:E4 mice were noted with these antibodies. As in previous studies with PDAPP and other human APP TG mice, neurofibrillary tangles were not seen. Because PDAPP:E3 and PDAPP:E4 mice have little to no A␤ deposits at 12-13 months of age in the absence of TBI (Holtzman et al., 2000; Fagan et al., 2002 ), TBI appears to accelerate A␤ deposition in the form of amyloid in the presence of human APOE4 to a greater extent than APOE3. Consistent with previous reports (Holtzman et al., 2000; Fagan et al., 2002) , three of the four PDAPP:EϪ/Ϫ mice had hippocampal diffuse A␤-IR deposits at 12 months of age; however, none were fibrillar. 
Hippocampal A␤ load
Analysis of all three groups revealed no significant difference between the two hemispheres in the amount of A␤ immunoreactivity. There was a significant main effect of genotype in that, consistent with previous reports (Holtzman et al., 2000; Fagan et al., 2002) , PDAPP:EϪ/Ϫ mice had a significantly greater A␤ load than PDAPP:E3 or PDAPP:E4 mice ( p Ͻ 0.0001). However, the A␤ deposits present in PDAPP:EϪ/Ϫ mice consisted of only thioflavine-S-negative, diffuse A␤ (i.e., nonfibrillar, nonamyloid deposits). The amount of diffuse A␤ in PDAPP:EϪ/Ϫ mice after TBI was not clearly increased compared with PDAPP:EϪ/Ϫ mice in the absence of TBI (Holtzman et al., 2000; Fagan et al., 2002) . A separate PDAPP:E3 versus PDAPP:E4 analysis revealed a significant main effect of genotype (PDAPP:E4 Ͼ PDAPP:E3; p Ͻ 0.05) but no significant hemisphere effect. Approximately 35% of the hippocampal A␤ load in PDAPP:E4 mice was contained within the ML, whereas no PDAPP:E3 or PDAPP:EϪ/Ϫ mice had ML deposition. Analysis of the percentage of A␤ deposition within the ML of the dentate gyrus revealed a significant main effect of genotype (PDAPP:E4 Ͼ PDAPP:E3 and PDAPP:EϪ/Ϫ; p Ͻ 0.006) (Fig. 1 ).
Cortical and hippocampal volume estimates Cortex
After TBI, the cortical volume ipsilateral to impact was significantly less than the contralateral, nonimpacted hemisphere for all groups ( p Ͻ 0.0001) (Fig. 2) . A main effect of genotype revealed that PDAPP:E4 mice had slightly but significantly more cortical tissue bilaterally than PDAPP:E3 or PDAPP:EϪ/Ϫ mice, which did not differ ( p Ͻ 0.001). The hemisphere-genotype interaction was not significant. The percentage of tissue loss in the cortex ipsilateral versus contralateral to injury revealed no significant genotype differences.
Hippocampus
After TBI, the hippocampus ipsilateral to impact was significantly smaller than the contralateral hippocampus for all groups ( p Ͻ 0.008) (Fig. 2) . A main effect of the genotype revealed that PDAPP:E3 mice had slightly but significantly less overall hippocampal tissue bilaterally than PDAPP:E4 or PDAPP:EϪ/Ϫ mice, which did not differ ( p Ͻ 0.001). The hemisphere-genotype interaction was not significant. The percentage of tissue loss in the hippocampus ipsilateral versus contralateral to injury revealed no significant genotype differences.
Neuronal counts (CA3 inferior blade)
After TBI, the inferior blade of CA3 ipsilateral to injury had significantly fewer neurons (ϳ35% less) than the uninjured hemisphere for all groups ( p Ͻ 0.0005) (Fig. 3 ). There were no significant genotype main effects or interactions. The percentage of CA3 cell loss revealed no significant genotype differences. 
DISCUSSION
Our previous work (Holtzman et al., 2000; Fagan et al., 2002) demonstrated that A␤ deposition in PDAPP mice that express human APOE normally does not begin until ϳ15 months of age, Ն6 months later than in animals expressing murine apoE. The appearance of A␤-IR deposits by 12-13 months in the current study suggests that TBI accelerated the A␤ deposition process in the presence of human APOE4. Furthermore, only PDAPP:E4 mice had significant A␤-IR deposits in the ML of the dentate gyrus within 3 months of TBI. These ML deposits are associated with thioflavine-S-positive staining, indicating the conversion of soluble A␤ to a ␤-sheet conformation and neuritic plaque formation. As in our previous studies, PDAPP:EϪ/Ϫ mice had higher levels of A␤ deposition than PDAPP:E3 or PDAPP:E4 mice, yet none of these deposits consisted of true amyloid. Thus, although the presence of APOE facilitates A␤ fibril formation, human APOE is likely also to play a role in A␤ clearance. Our results suggest that TBI and APOE4 (compared with APOE3) interact to result in greater and earlier amyloid deposition. Overall, these data suggest that the association with APOE4 and higher risk for cognitive impairment and AD after TBI may in part be attributable to APOE-A␤ interactions. Human studies have shown that both short-and long-term recovery from TBI seem to be influenced by APOE. APOE4ϩ individuals scored significantly worse on neuropsychological tests 3 weeks after mild to moderate TBI than APOE4Ϫ individuals (Liberman et al., 2002) , and APOE4 was predictive of longer periods of unconsciousness and worse clinical outcome after TBI (Friedman et al., 1999) . Furthermore, APOE4ϩ individuals were twice as likely as APOE4Ϫ individuals to be dead, comatose, or severely disabled 6 months after TBI (Teasdale et al., 1997) . In addition to the poor general clinical outcome associated with APOE4, memory performance within 6 months of head injury was worse in APOE4ϩ patients compared with APOE4Ϫ patients (Crawford et al., 2002) , whereas APOE4 led to worse motor function after TBI (Lichtman et al., 2000) . Mild, repetitive head injury also appears to interact with APOE. APOE4ϩ professional boxers had significantly worse neurological scores on a test of chronic brain injury that encompassed cognitive, motor, and behavioral domains than boxers who were APOE4Ϫ (Jordan et al., 1997) . Similarly, older APOE4ϩ professional football players scored lower on cognitive tests than APOE4Ϫ players (Kutner et al., 2000) .
Clinical and experimental TBI is also associated with accelerated A␤ deposition (Roberts et al., 1991) , with an even greater effect observed in APOE4ϩ individuals on both parenchymal and vascular A␤ deposits (Nicoll et al., 1995 (Nicoll et al., , 1996 Macfarlane et al., 1999; Leclercq et al., 2002) . A␤ deposition is also accelerated after seizure-induced neurodegeneration, even in young APOE4ϩ subjects (Gouras et al., 1997) . In addition to human studies, the effects of TBI on A␤ and AD pathology have also been studied using TG mouse models of AD. Smith et al. (1998) reported that TBI in PDAPP mice resulted in an 84% loss of CA3 neurons compared with only a 36% loss in non-TG mice. Nakagawa et al. (1999 Nakagawa et al. ( , 2000 have reported that TBI in both young and old PDAPP mice induces atrophy and reduces A␤ deposition in the ipsilateral versus contralateral hippocampus. A␤ deposition after repetitive brain injury using different APP TG mice (Tg2576) and milder cortical impact has also been reported (Uryu et al., 2002) . Our study extends these findings and demonstrates the amyloid-promoting effects of human APOE4.
How TBI results in an isoform-dependent increase in amyloid deposition is not clear. Both in vitro and in vivo studies demonstrate that APOE can interact with A␤ and influences the probability of whether A␤ will aggregate in a ␤-sheet conformation, resulting in neuritic toxicity (for review, see Wisniewski et al., 1997; Holtzman, 2001) . The level of apoE plays a significant role in this effect, because mouse apoE regulates A␤ deposition in a gene dose-dependent manner in vivo (Bales et al., 1997) . The effects of TBI on APOE-A␤ interactions may be secondary to an increase in APOE levels after TBI as well as alterations in APOE-dependent A␤ clearance. An increase in APOE levels has been noted after multiple types of brain injury coincident with glial activation (Teter, 2000) . In addition to neuronal degeneration, there is cellular reorganization with increased gliosis and alterations in the vasculature. APOE can potentially interact with different apoE receptors as well as the extracellular matrix. Because both of these factors change in regions of injury, APOEmediated A␤ clearance may be reduced after TBI, thereby favoring amyloid deposition. It is interesting that amyloid deposits were increased not unilaterally but bilaterally after TBI in the presence of APOE4. This suggests that mechanisms such as changes in APOE expression and alterations in APOE-dependent clearance are likely to occur bilaterally in this model of TBI.
The current study, in which the only known difference between the groups of PDAPP mice was the presence or absence of human APOE isoforms, provides evidence that isoform-specific APOE-A␤ interactions contribute to the premature development of AD pathology. Although the promotion of amyloid deposition per se is unlikely to lead to accelerated dementia, the neuritic dystrophy associated with amyloid as well as other events coincident with or downstream of amyloid formation in humans are likely to contribute to cognitive dysfunction. These processes include A␤ oligomer formation, tangle formation, cell loss, and synaptic loss. Some in vivo studies have found that apoE influences aspects of brain function and plasticity after different forms of injury Sheng et al., 1998; Stone et al., 1998; Buttini et al., 1999; Genis et al., 2000; Sabo et al., 2000) , including TBI (Chen et al., 1997) , and it is possible that APOE influences the outcome after different forms of brain injury via more than one mechanism. Our data suggest that understanding the mechanism(s) by which TBI promotes APOE isoform-dependent amyloid deposition will lead to important insights into how accelerated A␤-related AD-like changes occur and potential ways to prevent it.
